Right Heart Catheterization

While there are several tests that may lead a doctor to suspect pulmonary arterial hypertension (PAH), only a right heart catheterization (RHC) can definitively diagnose the disease. You will need this procedure and a diagnosis of PAH to start taking Tyvaso.

The RHC is performed in a medical setting and involves inserting a catheter through the blood vessels and into the heart. This procedure allows your doctor to measure heart function and blood pressure in the heart and pulmonary artery. It also helps evaluate the severity of PAH.

Make sure to check with your doctor to see if you require any special preparation for the procedure. Tell him or her about any medications you are taking before the procedure. Usually they will instruct you not to eat or drink for several hours before the procedure.

While every patient is different, and your experience may vary, the following is a general description of what you can expect the day of your RHC:

Next: Learn About the NYHA Functional Classification System

IMPORTANT SAFETY INFORMATION FOR TYVASO

Before you take Tyvaso, tell your healthcare provider about all of your medical conditions, including if you:

It is important to tell your healthcare provider about all the medicines you may be taking, including prescription and non-prescription medicines, vitamins, and herbal supplements, as they may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. Especially tell your healthcare provider if you take any of these medicines:

The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your healthcare provider about any side effects that bother you or do not go away. Your healthcare provider may be able to help you manage the side effects.

INDICATION

Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist, (ERA)) or sildenafil (a phosphodiesterase-5 (PDE-5) inhibitor). Your ability to do exercise decreases 4 hours after taking Tyvaso.

The effects of Tyvaso are unknown in patients under 18 years of age.

TYVISIdtcJUN16

Please see the Full Prescribing Information, Patient Package Insert, and the Tyvaso Inhalation System Instructions for Use manual.

For additional information about Tyvaso, visit www.tyvaso.com or call 1-877-UNITHER (1-877-864- 8437).

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

This information is provided for an informational purpose and is not intended as treatment advice. Patients should consult a healthcare professional for treatment advice.